Cargando…

Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care

BACKGROUND: Patients with gastrointestinal disease may have comorbid iron deficiency anaemia (IDA) and an increased risk of hospitalisation and re-attendance in hospital. The purpose of this study was to determine if oral and intravenous (IV) treatment of IDA in patients with gastrointestinal diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomkins, Susannah, Chapman, Callum, Myland, Melissa, Tham, Rachel, de Nobrega, Rachael, Jackson, Brinley, Keshav, Satish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731697/
https://www.ncbi.nlm.nih.gov/pubmed/29244881
http://dx.doi.org/10.1371/journal.pone.0189952
_version_ 1783286549137326080
author Tomkins, Susannah
Chapman, Callum
Myland, Melissa
Tham, Rachel
de Nobrega, Rachael
Jackson, Brinley
Keshav, Satish
author_facet Tomkins, Susannah
Chapman, Callum
Myland, Melissa
Tham, Rachel
de Nobrega, Rachael
Jackson, Brinley
Keshav, Satish
author_sort Tomkins, Susannah
collection PubMed
description BACKGROUND: Patients with gastrointestinal disease may have comorbid iron deficiency anaemia (IDA) and an increased risk of hospitalisation and re-attendance in hospital. The purpose of this study was to determine if oral and intravenous (IV) treatment of IDA in patients with gastrointestinal disease attending hospital were associated with differential rates of subsequent re-attendance. METHODS AND FINDINGS: Data from the Clinical Practice Research Datalink (primary care) and Hospital Treatment Insights (secondary care) databases in England were used to conduct this retrospective cohort study. Patients with a coded gastrointestinal disease and IDA who attended hospital (inpatient or outpatient) and were dispensed oral or IV iron between 01/01/2010-31/10/2013 were included. Elective and emergency re-attendances in secondary care within 30 days of the initial attendance were determined. Demographics, medical diagnoses and treatments were extracted. Re-attendance rates following oral or IV iron were compared using chi-square tests and a step-wise logistic regression model to adjust for confounders. 2,844 patients contributed 6,294 initial attendances; 80% of patients received oral iron, 14% received intravenous iron, and 6% received both. Of initial attendances recording oral iron, 77% resulted in re-attendance in hospital, compared to 34% of those recording IV iron (unadjusted odds ratio [OR]: 0.16; adjusted OR: 0.52 [95% CI: 0.44–0.61]). Initial attendances using IV treatment were more likely to result in elective re-attendance (84%) than those recording oral treatment (43%) (p<0.001). Median length of stay in hospital tended to be shorter for patients using IV iron (1.4 days; interquartile range 0.5–3.6 days; oral iron: 5.1 days; interquartile range: 2.2–9.6 days). CONCLUSIONS: Patients with gastrointestinal disease and IDA who received IV iron were less likely to re-attend hospital, more likely to re-attend electively, and tended to have a shorter length of stay in hospital. The mode of IDA treatment could have a real-world impact on healthcare utilisation.
format Online
Article
Text
id pubmed-5731697
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-57316972017-12-22 Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care Tomkins, Susannah Chapman, Callum Myland, Melissa Tham, Rachel de Nobrega, Rachael Jackson, Brinley Keshav, Satish PLoS One Research Article BACKGROUND: Patients with gastrointestinal disease may have comorbid iron deficiency anaemia (IDA) and an increased risk of hospitalisation and re-attendance in hospital. The purpose of this study was to determine if oral and intravenous (IV) treatment of IDA in patients with gastrointestinal disease attending hospital were associated with differential rates of subsequent re-attendance. METHODS AND FINDINGS: Data from the Clinical Practice Research Datalink (primary care) and Hospital Treatment Insights (secondary care) databases in England were used to conduct this retrospective cohort study. Patients with a coded gastrointestinal disease and IDA who attended hospital (inpatient or outpatient) and were dispensed oral or IV iron between 01/01/2010-31/10/2013 were included. Elective and emergency re-attendances in secondary care within 30 days of the initial attendance were determined. Demographics, medical diagnoses and treatments were extracted. Re-attendance rates following oral or IV iron were compared using chi-square tests and a step-wise logistic regression model to adjust for confounders. 2,844 patients contributed 6,294 initial attendances; 80% of patients received oral iron, 14% received intravenous iron, and 6% received both. Of initial attendances recording oral iron, 77% resulted in re-attendance in hospital, compared to 34% of those recording IV iron (unadjusted odds ratio [OR]: 0.16; adjusted OR: 0.52 [95% CI: 0.44–0.61]). Initial attendances using IV treatment were more likely to result in elective re-attendance (84%) than those recording oral treatment (43%) (p<0.001). Median length of stay in hospital tended to be shorter for patients using IV iron (1.4 days; interquartile range 0.5–3.6 days; oral iron: 5.1 days; interquartile range: 2.2–9.6 days). CONCLUSIONS: Patients with gastrointestinal disease and IDA who received IV iron were less likely to re-attend hospital, more likely to re-attend electively, and tended to have a shorter length of stay in hospital. The mode of IDA treatment could have a real-world impact on healthcare utilisation. Public Library of Science 2017-12-15 /pmc/articles/PMC5731697/ /pubmed/29244881 http://dx.doi.org/10.1371/journal.pone.0189952 Text en © 2017 Tomkins et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Tomkins, Susannah
Chapman, Callum
Myland, Melissa
Tham, Rachel
de Nobrega, Rachael
Jackson, Brinley
Keshav, Satish
Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care
title Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care
title_full Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care
title_fullStr Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care
title_full_unstemmed Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care
title_short Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care
title_sort treating iron deficiency in patients with gastrointestinal disease: risk of re-attendance in secondary care
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731697/
https://www.ncbi.nlm.nih.gov/pubmed/29244881
http://dx.doi.org/10.1371/journal.pone.0189952
work_keys_str_mv AT tomkinssusannah treatingirondeficiencyinpatientswithgastrointestinaldiseaseriskofreattendanceinsecondarycare
AT chapmancallum treatingirondeficiencyinpatientswithgastrointestinaldiseaseriskofreattendanceinsecondarycare
AT mylandmelissa treatingirondeficiencyinpatientswithgastrointestinaldiseaseriskofreattendanceinsecondarycare
AT thamrachel treatingirondeficiencyinpatientswithgastrointestinaldiseaseriskofreattendanceinsecondarycare
AT denobregarachael treatingirondeficiencyinpatientswithgastrointestinaldiseaseriskofreattendanceinsecondarycare
AT jacksonbrinley treatingirondeficiencyinpatientswithgastrointestinaldiseaseriskofreattendanceinsecondarycare
AT keshavsatish treatingirondeficiencyinpatientswithgastrointestinaldiseaseriskofreattendanceinsecondarycare